{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:11:17Z","timestamp":1777547477237,"version":"3.51.4"},"reference-count":38,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.5362-25","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T18:09:48Z","timestamp":1744394988000},"page":"3044-3050","source":"Crossref","is-referenced-by-count":2,"title":["Development of Diffuse Large B Cell Lymphoma in a Patient with Systemic Lupus Erythematosus within Two Years after the Initiation of Anifrolumab and Mycophenolate Mofetil Treatment"],"prefix":"10.2169","volume":"64","author":[{"given":"Takuya","family":"Matsubara","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikue","family":"Sekai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Omaru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Okai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Minaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 7: 360-368, 2011.","DOI":"10.1038\/nrrheum.2011.62"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bichile T, Petri M. Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. Curr Opin Rheumatol 26: 111-117, 2014.","DOI":"10.1097\/BOR.0000000000000026"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gorodetskiy V, Probatova N, Obukhova T, Vasilyev V. Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases. Lupus Sci Med 8: e000561, 2021.","DOI":"10.1136\/lupus-2021-000561"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hsu CY, Lin MS, Su YJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford) 56: 620-628, 2017.","DOI":"10.1093\/rheumatology\/kew457"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Martin-Lopez M, Galindo M, Pego-Reigosa JM, et al. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study. Rheumatology (Oxford) 62: 217-224, 2022.","DOI":"10.1093\/rheumatology\/keac258"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mockel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev 20: 102736, 2021.","DOI":"10.1016\/j.autrev.2020.102736"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lofstrom B, Backlin C, Pettersson T, Lundberg IE, Baecklund E. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 38: 1891-1897, 2011.","DOI":"10.3899\/jrheum.101190"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104: 2247-2253, 2004.","DOI":"10.1182\/blood-2004-02-0762"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology. Leuk Res 75: 45-49, 2018.","DOI":"10.1016\/j.leukres.2018.11.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Guo J, Ren Z, Li J, Li T, Liu S, Yu Z. The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. Arthritis Res Ther 22: 159, 2020.","DOI":"10.1186\/s13075-020-02228-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ganguly D. Do type I interferons link systemic autoimmunities and metabolic syndrome in a pathogenetic continuum?. Trends Immunol 39: 28-43, 2018.","DOI":"10.1016\/j.it.2017.07.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet 403: 2326-2338, 2024.","DOI":"10.1016\/S0140-6736(24)00398-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382: 211-221, 2020.","DOI":"10.1056\/NEJMoa1912196"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease. Nat Rev Genet 20: 657-674, 2019.","DOI":"10.1038\/s41576-019-0151-1"},{"key":"15","unstructured":"15. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78: 1151-1159, 2019."},{"key":"16","unstructured":"16. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71: 1400-1412, 2019."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Colagrande S, Calistri L, Grazzini G, et al. MRI features of primary hepatic lymphoma. Abdom Radiol (NY) 43: 2277-2287, 2018.","DOI":"10.1007\/s00261-018-1476-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rajesh S, Bansal K, Sureka B, Patidar Y, Bihari C, Arora A. The imaging conundrum of hepatic lymphoma revisited. Insights Imaging 6: 679-692, 2015.","DOI":"10.1007\/s13244-015-0437-6"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2004.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386: 351-363, 2022.","DOI":"10.1056\/NEJMoa2115304"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Vitolo U, Frascione PMM, Bonello F. Pola-R-CHP for frontline therapy in DLBCL: are we saving money by spending more?. Br J Haematol 202: 731-733, 2023.","DOI":"10.1111\/bjh.18934"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol 31: 1-12, 2021.","DOI":"10.1080\/14397595.2020.1812201"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med 8: e000464, 2021.","DOI":"10.1136\/lupus-2020-000464"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol 28: 1-8, 2018.","DOI":"10.1080\/14397595.2017.1352477"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tanaka K, Ichikawa A, Umezawa N, et al. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci 114: 3719-3727, 2023.","DOI":"10.1111\/cas.15894"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tokuhira M, Saito S, Suzuki K, et al. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. Leuk Lymphoma 60: 2508-2515, 2019.","DOI":"10.1080\/10428194.2019.1585841"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop 59: 72-92, 2019.","DOI":"10.3960\/jslrt.19007"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 53: 616-623, 2012.","DOI":"10.3109\/10428194.2011.625101"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 62: 2517-2524, 2010.","DOI":"10.1002\/art.27511"},{"key":"30","doi-asserted-by":"crossref","first-page":"e167910","DOI":"10.1172\/jci.insight.167910","volume":"9","author":"A Hara","year":"2024","unstructured":"30. Hara A, Watanabe T, Minaga K, et al. A positive cytokine\/chemokine feedback loop establishes plasmacytoid DC-driven autoimmune pancreatitis in IgG4-related disease. JCI Insight 9: e167910, 2024.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity 54: 859-874, 2021.","DOI":"10.1016\/j.immuni.2021.01.012"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Vegso G, Sebestyen A, Paku S, et al. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 31: 1003-1008, 2007.","DOI":"10.1016\/j.leukres.2006.12.019"},{"key":"33","unstructured":"33. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378: 1396-1407, 2018."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol 16: e555-e567, 2015.","DOI":"10.1016\/S1470-2045(15)00005-4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Takada R, Watanabe T, Sekai I, et al. Case report: concurrent occurrence of abdominal double expressor lymphoma and jejunum follicular lymphoma. Front Oncol 11: 656219, 2021.","DOI":"10.3389\/fonc.2021.656219"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Satou A, Tabata T, Miyoshi H, et al. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. Mod Pathol 32: 1135-1146, 2019.","DOI":"10.1038\/s41379-019-0264-2"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 66: 815-817, 2007.","DOI":"10.1136\/ard.2006.067777"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Thieme CJ, Schulz M, Wehler P, et al. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. Kidney Int 102: 1392-1408, 2022.","DOI":"10.1016\/j.kint.2022.08.025"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5362-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:27:59Z","timestamp":1760761679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5362-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":38,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5362-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"5362-25"}}